SCHEMBL6821053

SCHEMBL6821053

Clc1nc(NCc2ccncc2)c2ncn(C3CCCC3)c2n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 9/20 0.63
CTSL P07711 4/20 0.62
TDP1 Q9NUW8 1/20 0.58
CCNE1 P24864 5/20 0.54
CDK2 P24941 5/20 0.54
CCNE2 O96020 3/20 0.54
CCNB2 O95067 1/20 0.54
CDK4 P11802 1/20 0.54
CCNB1 P14635 1/20 0.54
CCND1 P24385 1/20 0.54
FLT3 P36888 1/20 0.54
CCNB3 Q8WWL7 1/20 0.54
CDK5 Q00535 2/20 0.53
CCNA2 P20248 1/20 0.51
CCNA1 P78396 1/20 0.51
NT5E P21589 1/20 0.49
ADORA3 P0DMS8 1/20 0.48
TMIGD3 P0DMS9 1/20 0.48
HTR2C P28335 1/20 0.48
ADORA2A P29274 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5193141 0.90 CDK1 (0.78) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL6817715 0.90 CTSL (0.76) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL6820578 0.88 CTSL (0.64) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL15940797 0.88 CTSL (0.64) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL6945642 0.85 TDP1 (0.80) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL6820811 0.85 CTSL (0.60) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL5197924 0.84 CDK1 (0.60) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL6817805 0.84 ADORA3 (0.68) CDK1CTSLADORA3TMIGD3HTR2C
SCHEMBL27146868 0.84 CDK1 (0.66) CDK1CTSLTDP1CCNE1CDK2
SCHEMBL15940775 0.83 CDK1 (0.71) CDK1CTSLTDP1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed
EP-1056745-A2 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043676-A2 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed